VJHemOnc is committed to improving our service to you

IACH Focus on Leukemia 2020 | The future of MDS management

VJHemOnc is committed to improving our service to you

Thomas Cluzeau

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses how at the moment there are not a lot of treatment options for myelodysplastic syndromes (MDS). However, in the future, there could be several treatment options for both lower and higher-risk MDS and treatment choice may depend on the molecular status of the disease. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter